943541-40-0

Basic information

• Product Name: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate
• Synonyms: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate;6-[(Ethoxycarbonyl)difluoromethyl]quinoline;Ethyl difluoro(quinolin-6-yl)acetate;6-Quinolineacetic acid, α,α-difluoro-, ethyl ester
• CAS NO: 943541-40-0
• Molecular Formula: C₁₃H₁₁F₂NO₂
• Molecular Weight: 251.23
• Mol File: 943541-40-0.mol

Chemical Properties

• Boiling Point: 348.7 °C at 760 mmHg
• Flash Point: 164.7 °C
• Appearance: /
• Density: 1.269 g/cm³
• Vapor Pressure: 4.93E-05mmHg at 25°C
• Refractive Index: 1.546
• PKA: 4.08±0.10(Predicted)
• CAS DataBase Reference: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(943541-40-0)
• EPA Substance Registry System: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(943541-40-0)

Safety Data

• Hazardous Substances Data: 943541-40-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl2,2-difluoro-2-(quinolin-6-yl)acetate is used as an intermediate in the synthesis of pharmaceuticals for its unique structural features that can contribute to the development of novel drug molecules. Its quinolin-6-yl group and difluoro substitution may impart specific biological activities or enhance the pharmacokinetic properties of the resulting compounds.
Used in Chemical Synthesis:
In the chemical synthesis industry, ethyl2,2-difluoro-2-(quinolin-6-yl)acetate serves as a key building block for the creation of complex organic molecules. Its reactivity and structural attributes make it a valuable component in the synthesis of various specialty chemicals, including agrochemicals, dyes, and other fine chemicals.
Used in Research and Development:
Ethyl2,2-difluoro-2-(quinolin-6-yl)acetate is utilized as a research compound in academic and industrial laboratories. It is employed to explore new chemical reactions, investigate the effects of fluorination on molecular properties, and study the interactions of the quinolin-6-yl group with other molecules, which can lead to advancements in medicinal chemistry and materials science.

InChI:InChI=1/C13H11F2NO2/c1-2-18-12(17)13(14,15)10-5-6-11-9(8-10)4-3-7-16-11/h3-8H,2H2,1H3

Upstream product

• 13327-31-6 6-iodoquinoline 
• 667-27-6 Ethyl bromodifluoroacetate 
• 1093204-29-5 ethyl 2-oxo-2-(6-quinolyl)acetate 
• 5332-25-2 6-bromoquinoline 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 

Downstream Products

• 1093204-35-3 sodium 2,2-difluoro-2-(quinolin-6-yl)acetate 
• 1151800-43-9 6-[(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-difluoro-methyl]-quinoline 
• 1256455-26-1 5-(difluoro(quinolin-6-yl)methyl)-4-(iminotriphenylphosphorano)-4H-1,2,4-triazole-3-thiol 
• 1256487-41-8 5-(difluoro(quinolin-6-yl)methyl)-4-(iminotriphenylphosphorano)-4H-1,2,4-triazole-3-thiol 
• 1256487-35-0 VRT-846198 
• 1256487-42-9 1-(3-(difluoro(quinolin-6-yl)methyl)-[1,2,4]triazolo[3,4-d][1,3,4]thiadiazol-6-yl)-1,3-bis(1-methyl-1H-pyrazol-4-yl)urea 
• 943540-75-8 JNJ-38877605 
• 1256455-21-6 C₁₈H₁₃F₂N₇S 
• 943541-39-7 2,2-difluoro-2-(quinolin-6-yl)acetic acid hydrazide 

Relevant articles and documents

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Herein, we report a novel series of highly potent and selective triazolothiadiazole c-Met inhibitors. Starting with molecule 5, we have applied structure-based drug design principles to identify the triazolothiadiazole ring system. We successfully replaced the metabolically unstable phenolic moiety with a quinoline group. Further optimization around the 5,6 bicyclic moiety led to the identification of 21. Compound 21 suffered from PDE3 selectivity issues and subsequent, structurally informed design led to the discovery of compound 23. Compound 23 has exquisite kinase selectivity, excellent potency, favorable ADME profile, and showed dose-dependent antitumor efficacy in a SNU-5 gastric cancer xenograft model.

3. 4 - dihydro - 1H - benzo [c] [1, 2] oxa boric acid compound or a pharmaceutically acceptable salt thereof and its preparation and use

The invention relates to 3,4-dihydro-1H-benzo[c][1,2]oxaboric acid compounds or pharmaceutically acceptable salts thereof, a preparation method of the compounds and application of the compounds and the salts. Concretely, the invention relates to the compound with the general formula (I) and the pharmaceutically acceptable salts, and the preparation method of the compounds. The invention also relates to a pharmaceutical composition containing the compounds or the pharmaceutically acceptable salts as a receptor tyrosine kinase inhibitor, especially as a c-Met inhibitor. The invention also relates to application of the compounds or the pharmaceutical composition to prepare medicines for preventing and/or treating diseases related to c-Met abnormity. The compounds have obvious propagation inhibition activity on SNU-5 cells, and have obvious inhibition effect on c-Met kinases activity.

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE

The present invention relates to anhydrous and hydrated forms of Compound 1, which qre useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.

AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE

The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula (I) and methods of using the compositions in the treatment of proliferative disorders

SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE

The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula (I) and methods of using the compositions in the treatment of proliferative disorders.

POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE

The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound.